These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11702749)

  • 21. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
    Best B; Haubrich R
    Expert Opin Investig Drugs; 2006 Jan; 15(1):59-70. PubMed ID: 16370934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ; Cocohoba JM
    Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
    Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
    AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.
    Stürmer M; Stephan C; Gute P; Knecht G; Bickel M; Brodt HR; Doerr HW; Gürtler L; Lecocq P; van Houtte M
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5362-6. PubMed ID: 21825300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 48-week RESIST data confirms TPV benefit.
    Gadd C
    IAPAC Mon; 2006 Jan; 12(1):9. PubMed ID: 17249129
    [No Abstract]   [Full Text] [Related]  

  • 28. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some existing drugs work on resistant HIV.
    AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
    Llibre JM; Pérez-Alvarez N
    HIV Med; 2007 Nov; 8(8):568-70; author reply 571-2. PubMed ID: 17944691
    [No Abstract]   [Full Text] [Related]  

  • 31. Salvage therapy update.
    Emery C
    Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
    [No Abstract]   [Full Text] [Related]  

  • 32. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
    Kandula VR; Khanlou H; Farthing C
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):9-21. PubMed ID: 15757454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates on developments in HIV therapeutics.
    Boyle BA
    AIDS Read; 2005 Jan; 15(1):23-7. PubMed ID: 15685731
    [No Abstract]   [Full Text] [Related]  

  • 34. New drugs: ramelteon, tipranavir, nepafenac, and deferasirox.
    Hussar DA
    J Am Pharm Assoc (2003); 2006; 46(1):107-11. PubMed ID: 16529348
    [No Abstract]   [Full Text] [Related]  

  • 35. Aptivus capsules granted full FDA approval.
    AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
    Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
    Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
    AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
    [No Abstract]   [Full Text] [Related]  

  • 38. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tipranavir.
    Flexner C; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
    [No Abstract]   [Full Text] [Related]  

  • 40. Tipranavir demonstrates potent and durable treatment response in HIV-positive women.
    AIDS Patient Care STDS; 2007 Aug; 21(8):602-3. PubMed ID: 17907309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.